Results from World's Largest Study on Sleep Apnea and Digital Connected Care
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Jefferies Cuts Price Target on ResMed (RMD) to $56 Following 1Q Miss
October 26, 2016 7:11 AM EDTJefferies maintained an Underperform rating on ResMed (NYSE: RMD), and cut the price target to $56.00 (from $58.00), following the company's 1Q earnings report. ResMed reported a $10mn revenue miss on a $0.02 EPS miss. Organic growth of 3% drove EPS growth of 7%; however, excluding... More
